Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.
from Reuters: Health News https://ift.tt/2RbqJsF
via
IFTTT
0 comments:
Post a Comment